Deciphera Pharmaceuticals (DCPH) – Investment Analysts’ Weekly Ratings Changes

Deciphera Pharmaceuticals (NASDAQ: DCPH) recently received a number of ratings updates from brokerages and research firms:

• 4/30/2024 – Deciphera Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Guggenheim.
• 4/30/2024 – Deciphera Pharmaceuticals had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 4/30/2024 – Deciphera Pharmaceuticals was upgraded by analysts at Barclays PLC from an “underweight” rating to an “equal weight” rating. They now have a $26.00 price target on the stock, up previously from $9.00.
• 4/29/2024 – Deciphera Pharmaceuticals was downgraded by analysts at Leerink Partnrs from an “outperform” rating to a “market perform” rating.
• 4/29/2024 – Deciphera Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $25.60 price target on the stock, down previously from $26.00.
• 4/29/2024 – Deciphera Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jonestrading. They now have a $25.60 price target on the stock.
• 3/20/2024 – Deciphera Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $16.00. They now have a “neutral” rating on the stock.

Deciphera Pharmaceuticals Stock Down 0.0 %

Shares of DCPH opened at $25.37 on Thursday. The stock has a market cap of $2.09 billion, a P/E ratio of -11.08 and a beta of 0.20. The business’s fifty day moving average is $17.08 and its 200 day moving average is $15.14. Deciphera Pharmaceuticals, Inc. has a 12-month low of $9.90 and a 12-month high of $25.47.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. The business had revenue of $48.30 million during the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. Deciphera Pharmaceuticals’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.60) EPS. On average, analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.16 EPS for the current year.

Institutional Investors Weigh In On Deciphera Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C boosted its stake in shares of Deciphera Pharmaceuticals by 2.8% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock worth $87,738,000 after buying an additional 190,580 shares during the last quarter. Armistice Capital LLC lifted its holdings in Deciphera Pharmaceuticals by 12.7% during the fourth quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $83,876,000 after acquiring an additional 588,000 shares during the period. Goldman Sachs Group Inc. boosted its position in Deciphera Pharmaceuticals by 14.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock worth $37,220,000 after purchasing an additional 290,968 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Deciphera Pharmaceuticals by 6.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,561,654 shares of the company’s stock valued at $25,191,000 after purchasing an additional 92,410 shares during the period. Finally, Frazier Life Sciences Management L.P. increased its position in shares of Deciphera Pharmaceuticals by 176.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company’s stock valued at $16,482,000 after purchasing an additional 651,800 shares during the last quarter. 70.96% of the stock is owned by institutional investors.

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.